Trial Profile
A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitazalimab (Primary) ; Mitazalimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Alligator Bioscience
- 29 Jan 2019 According to an Alligator Bioscience media release, the top line data from this study were presented at the Society for Immunotherapy of Cancer (SITC) in November 2017.
- 29 Jan 2019 According to an Alligator Bioscience media release, results were published in the International Journal of Cancer.
- 07 Nov 2017 Results presented in an Alligator Bioscience Media Release.